EP1286590A4 - Peptide analogs and mimetics suitable for in vivo use in the treatment of diseases associated with abnormal protein folding into amyloid, amyloid-like deposits or beta-sheet rich pathological precursor thereof - Google Patents

Peptide analogs and mimetics suitable for in vivo use in the treatment of diseases associated with abnormal protein folding into amyloid, amyloid-like deposits or beta-sheet rich pathological precursor thereof

Info

Publication number
EP1286590A4
EP1286590A4 EP00976928A EP00976928A EP1286590A4 EP 1286590 A4 EP1286590 A4 EP 1286590A4 EP 00976928 A EP00976928 A EP 00976928A EP 00976928 A EP00976928 A EP 00976928A EP 1286590 A4 EP1286590 A4 EP 1286590A4
Authority
EP
European Patent Office
Prior art keywords
amyloid
deposits
precursor
beta
treatment
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP00976928A
Other languages
German (de)
French (fr)
Other versions
EP1286590A2 (en
Inventor
Claudio Soto-Jara
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Axonyx Inc
Original Assignee
Axonyx Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Axonyx Inc filed Critical Axonyx Inc
Publication of EP1286590A2 publication Critical patent/EP1286590A2/en
Publication of EP1286590A4 publication Critical patent/EP1286590A4/en
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C229/00—Compounds containing amino and carboxyl groups bound to the same carbon skeleton
    • C07C229/02—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton
    • C07C229/34—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton containing six-membered aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4711—Alzheimer's disease; Amyloid plaque core protein
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/02—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link
    • C07K5/0207—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link containing the structure -NH-(X)4-C(=0), e.g. 'isosters', replacing two amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/06—Systems containing only non-condensed rings with a five-membered ring
    • C07C2601/08—Systems containing only non-condensed rings with a five-membered ring the ring being saturated

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Neurology (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hospice & Palliative Care (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Psychiatry (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
EP00976928A 1999-11-05 2000-11-04 Peptide analogs and mimetics suitable for in vivo use in the treatment of diseases associated with abnormal protein folding into amyloid, amyloid-like deposits or beta-sheet rich pathological precursor thereof Withdrawn EP1286590A4 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US16391199P 1999-11-05 1999-11-05
US163911P 1999-11-05
PCT/US2000/030416 WO2001034631A2 (en) 1999-11-05 2000-11-04 PEPTIDE ANALOGS AND MIMETICS SUITABLE FOR IN VIVO USE IN THE TREATMENT OF DISEASES ASSOCIATED WITH ABNORMAL PROTEIN FOLDING INTO AMYLOID, AMYLOID-LIKE DEPOSITS OR β-SHEET RICH PATHOLOGICAL PRECURSOR THEREOF

Publications (2)

Publication Number Publication Date
EP1286590A2 EP1286590A2 (en) 2003-03-05
EP1286590A4 true EP1286590A4 (en) 2005-05-11

Family

ID=22592138

Family Applications (1)

Application Number Title Priority Date Filing Date
EP00976928A Withdrawn EP1286590A4 (en) 1999-11-05 2000-11-04 Peptide analogs and mimetics suitable for in vivo use in the treatment of diseases associated with abnormal protein folding into amyloid, amyloid-like deposits or beta-sheet rich pathological precursor thereof

Country Status (11)

Country Link
EP (1) EP1286590A4 (en)
JP (1) JP2004513873A (en)
KR (2) KR20020079731A (en)
CN (1) CN1437442A (en)
AU (1) AU781044B2 (en)
BR (1) BR0015513A (en)
CA (1) CA2389041A1 (en)
EA (1) EA004739B1 (en)
IL (1) IL149392A0 (en)
MX (1) MXPA02004468A (en)
WO (1) WO2001034631A2 (en)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8003612B2 (en) 1997-10-08 2011-08-23 Proteotech Inc. Small peptides for the treatment of Alzheimer's disease and other beta-amyloid protein disorders
DE10101430B4 (en) * 2001-01-13 2008-10-02 Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung e.V. Soluble cyclic analogues for the modulation of amyloidogenesis
AU2004203461B2 (en) * 2002-01-31 2009-09-03 Tel Aviv University Future Technology Development L.P. Peptides Antibodies Directed Thereagainst and Methods Using Same for Diagnosing and Treating Amyloid-Associated Diseases
US20040052928A1 (en) 2002-09-06 2004-03-18 Ehud Gazit Peptides and methods using same for diagnosing and treating amyloid-associated diseases
DE10230141B4 (en) * 2002-07-04 2004-07-15 Priontype Gmbh Method and kit for the enrichment and detection of modified prion proteins (PrPSc)
WO2004005336A2 (en) * 2002-07-08 2004-01-15 Applied Research Systems Ars Holding N.V. β-SHEET BREAKING PEPTIDES
AU2003298260A1 (en) * 2002-12-02 2004-06-23 Laboratoires Serono Sa Aza-peptides
JP5137400B2 (en) 2003-06-30 2013-02-06 テル アヴィヴ ユニヴァーシティ フューチャー テクノロジー ディヴェロップメント エル．ピー． Peptides for diagnosing and treating amyloid-related diseases, antibodies thereto, and methods of use thereof
AU2005265182B2 (en) * 2004-06-17 2012-06-21 Mannkind Corporation Epitope analogs
ATE553114T1 (en) * 2005-02-28 2012-04-15 Alphabeta Ab COMPOUNDS FOR REDUCING AGGREGATION OF AMYLOID BETA PEPTIDE
CA2607940C (en) * 2005-05-18 2009-12-15 Aegera Therapeutics Inc. Bir domain binding compounds
EP1746422A1 (en) * 2005-07-19 2007-01-24 Universita'degli Studi Di Milano Method for the identification of proteins folding inhibitors
US8290713B2 (en) * 2006-08-04 2012-10-16 Lonza Biologics PLLC Method for predicting protein aggregation and designing aggregation inhibitors
BR112013012033A2 (en) 2010-11-15 2016-08-09 Merz Pharma Gmbh & Co Kgaa dipeptide analogues for the treatment of conditions associated with the formation of amyloid fibril
SG187271A1 (en) * 2011-07-07 2013-02-28 Agency Science Tech & Res Anti-amyloidogenic, alpha-helix breaking ultra-small peptide therapeutic
CN104053449B (en) * 2011-08-17 2016-12-07 硬木药品公司 The treatment of gastrointestinal tract disease
DE102013016002A1 (en) * 2013-09-26 2015-03-26 Forschungszentrum Jülich GmbH Cyclic amyloid beta-binding peptides and their use
JP6660877B2 (en) * 2013-09-26 2020-03-11 フォルシュングスツェントルム・ユーリッヒ・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツング Amyloid-β-binding peptide and its use for the treatment and diagnosis of Alzheimer's dementia
MY179462A (en) * 2013-10-11 2020-11-06 Malaysian Palm Oil Board Protective effects of oil palm composition on alzheimer?s disease
KR101627106B1 (en) 2014-03-26 2016-06-03 연세대학교 산학협력단 polypeptide having multiple directionality and self-assembled nanostructure containing the same
DE102015003676A1 (en) * 2015-03-20 2016-09-22 Forschungszentrum Jülich GmbH Fachbereich Patente Specifically A-beta species-binding peptides for the therapy and / or diagnosis of Alzheimer's dementia
AU2019271189A1 (en) 2018-05-15 2021-01-07 Lloyd Hung Loi TRAN Therapeutic agent composition and method of use, for treatment of mild cognitive impairment, depression, and psychological disorders

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5854204A (en) * 1995-03-14 1998-12-29 Praecis Pharmaceuticals, Inc. Aβ peptides that modulate β-amyloid aggregation

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5948763A (en) * 1995-06-07 1999-09-07 New York University Peptides and pharmaceutical compositions thereof for treatment of disorders or diseases associated with abnormal protein folding into amyloid or amyloid-like deposits
EP0929574B1 (en) * 1996-08-27 2005-06-29 Praecis Pharmaceuticals Incorporated MODULATORS OF beta-AMYLOID PEPTIDE AGGREGATION COMPRISING D-AMINO ACIDS

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5854204A (en) * 1995-03-14 1998-12-29 Praecis Pharmaceuticals, Inc. Aβ peptides that modulate β-amyloid aggregation

Non-Patent Citations (10)

* Cited by examiner, † Cited by third party
Title
ADESSI ET AL., JOURNAL OF BIOLOGICAL CHEMISTRY, vol. 278, 2003, pages 13905 - 13911 *
ALI ET AL., ACTA CHIMICA SCANDICANICA, vol. 27, 1973, pages 1509 - 1518 *
BASU ET AL, BIOPOLYMERS, vol. 31, 1991, pages 1763 - 1774, XP002056915 *
FAUCHERE J-L ET AL: "Evaluation of the stability of peptides and pseudopeptides as a tool in peptide drug design", ADVANCES IN DRUG RESEARCH 1992 UNITED KINGDOM, vol. 23, 1992, pages 127 - 159, XP009036334, ISSN: 0065-2490 *
GANTE J: "PEPTIDOMIMETICS-TAILORED ENZYME INHIBITORS", ANGEWANDTE CHEMIE. INTERNATIONAL EDITION, VERLAG CHEMIE. WEINHEIM, DE, vol. 33, no. 17, 16 September 1994 (1994-09-16), pages 1699 - 1720, XP000465275, ISSN: 0570-0833 *
PODUSLO J F ET AL: "BETA-SHEET BREAKER PEPTIDE INHIBITOR OF ALZHEIMER'S AMYLOIDOGENESIS WITH INCREASED BLOOD-BRAIN BARRIER PERMEABILITY AND RESISTANCE TO PROTEOLYTIC DEGRADATION IN PLASMA", JOURNAL OF NEUROBIOLOGY, JOHN WILEY AND SONS., NEW YORK, NY, US, vol. 39, no. 3, 5 June 1999 (1999-06-05), pages 371 - 382, XP009008758, ISSN: 0022-3034 *
ROSSI ET AL., BIOPOLYMERS, vol. 40, 1996, pages 465 - 478, XP009074244 *
SOTO C ET AL: "BETA-SHEET BREAKER PEPTIDES INHIBIT FIBRILLOGENESIS IN A RAT BRAIN MODEL OF AMYLOIDOSIS: IMPLICATIONS FOR ALZHEIMER'S THERAPY", NATURE MEDICINE, NATURE PUBLISHING, CO, US, vol. 4, no. 7, 1998, pages 822 - 826, XP000914747, ISSN: 1078-8956 *
SOTO C: "Alzheimer's and prion disease as disorders of protein conformation: implications for the design of novel therapeutic approaches", JOURNAL OF MOLECULAR MEDICINE, SPRINGER VERLAG, DE, vol. 77, no. 5, May 1999 (1999-05-01), pages 412 - 418, XP002203443, ISSN: 0946-2716 *
TONIOLO ET AL., PEPTIDE RESEARCH, vol. 5, 1992, pages 56 - 61 *

Also Published As

Publication number Publication date
KR20020079731A (en) 2002-10-19
BR0015513A (en) 2004-07-06
AU781044B2 (en) 2005-05-05
KR20060133114A (en) 2006-12-22
MXPA02004468A (en) 2004-09-10
AU1463501A (en) 2001-06-06
WO2001034631A3 (en) 2002-12-27
WO2001034631A2 (en) 2001-05-17
CN1437442A (en) 2003-08-20
EP1286590A2 (en) 2003-03-05
EA200200536A1 (en) 2002-12-26
IL149392A0 (en) 2002-11-10
JP2004513873A (en) 2004-05-13
CA2389041A1 (en) 2001-05-17
EA004739B1 (en) 2004-08-26

Similar Documents

Publication Publication Date Title
EP1286590A4 (en) Peptide analogs and mimetics suitable for in vivo use in the treatment of diseases associated with abnormal protein folding into amyloid, amyloid-like deposits or beta-sheet rich pathological precursor thereof
HK1070080A1 (en) Ganglioside-associated recombinant antibodies and the use thereof in the preparation of medicament for the diagnosis and treatment of tumors
WO2002046222A3 (en) Compositions and methods for diagnosing alzheimer's disease
EP1360965A4 (en) Methods of treating diseases in association with decrease in the expression of aop-1 gene or aop-1 and remedies for the diseases
TWI340640B (en) Combination, kit and pharmaceutical composition for treatment of parkinson's disease
EP1578988A4 (en) Protein based tnf-alpha variants for the treatment of tnf-alpha related disorders
EP2045267A3 (en) Humanized antibodies that recognize beta amyloid peptide
WO2002074337A8 (en) Hmgb1 protein inhibitors and/or antagonists for the treatment of vascular diseases
EP1404343A4 (en) Therapeutic combinations for the treatment of hormone deficiencies
GB9927603D0 (en) Use of a milk protein hydrolysate in the treatment of diabetes
MXPA03009772A (en) Methods and compositions for treating oral and eosophageal lesions.
IL138814A0 (en) Peptides for the treatment, prophylaxis, diagnosis and monitoring of autoimmune diseases
WO2003039454A8 (en) Beta-secretase inhibitors and methods of use
AU4541101A (en) Design and discovery of protein based tnf-alpha variants for the treatment of tnf-alpha related disorders
IL148401A0 (en) Hsp70-derived peptides and uses thereof in the diagnosis and treatment of autoimmune diseases
GB0216972D0 (en) Peptides and peptide derivaties for the treatment of &-synuclein-related diseases
AU2002212471A1 (en) Peptides for use in the treatment of alzheimer's disease
ZA991749B (en) Pharmaceutical composition for prophylaxis and therapy of diseases associated with ocular fundus tissue cytopathy.
GB9929497D0 (en) Improved amino acid mixtures for the treatment and/or management of certain diseases
AU2001253886A1 (en) Methylxanthines in the diagnosis and treatment of autistic disorder
AU2002350751A8 (en) Compounds which can be used to diagnose and monitor diseases associated with the formation of amyloid protein fibrils
EP1330251A4 (en) Combination therapy for the treatment of estrogen-sensitive disease
GB0008326D0 (en) Diagnosis and treatment of autism and related disorders
WO2001011039A3 (en) New sequence variants of the human 1-adrenoreceptor gene and use thereof
AU2003217432A8 (en) Angiopoietin-1 in the treatment of disease

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20020531

AK Designated contracting states

Kind code of ref document: A2

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE TR

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE TR

AX Request for extension of the european patent

Extension state: AL LT LV MK RO SI

A4 Supplementary search report drawn up and despatched

Effective date: 20050330

17Q First examination report despatched

Effective date: 20050705

17Q First examination report despatched

Effective date: 20050705

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20070522